| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |